Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice

Vaccine

Volumn 29, Issue 34, 2011, Pages 5778-5784

  Liu, Ying ^a,b   Luo, Xing ^a,b   Yang, Chunting ^b   Yu, Sanke ^a   Xu, Honglin ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b National Vaccine and Serum Institute ^*  (China)

Author keywords

Adjuvant; CpG oligodeoxynucleotides; CpG ODN; Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CYTOTOXICITY; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR BACTERIUM; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; LISTERIA MONOCYTOGENES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS;

EID: 79960565251     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.087     Document Type: Article

References (28)

1. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5(6):471-484.
2. Klinman D.M. Immunotherapeutic use of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4(4):1-10.
3. Davis H.L. TLR9 agonists for immune enhancement of vaccines. New Generation Vaccines 2010, Informa Healthcare USA Inc, New York, 263-272. fourth ed.
4. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
5. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34(1):251-262.
6. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z.K., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 2001, 31(7):2154-2163.
7. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur J Immunol 2003, 33:1633-1641.
8. Marshall J.D., Fearon K., Abbate C., Subramanian S., Yee P., Gregorio J., et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003, 73(6):781-792.
9. Gu M., Hine P.M., Jackson W.J., Giri L., Nabors G.S. Increased potency of BioThrax® anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CpG 10109. Vaccine 2007, 25:526-534.
10. Verthelyi D., Wang V.W., Lifson J.D., Klinman D.M. CpG oligodeoxynucleoties improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS 2004, 18(7):1003-1008.
11. Hartmann G., Marschner A., Viveros P.R., Hennig C.S., Eisenblatter M., Suh Y.S., et al. CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo. Vaccine 2005, 23:3310-3317.
12. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvant in primates. J Immunol 2002, 168:1659-1663.
13. Barber D.L., Wherry E.J., Ahmed R. Cutting edge: rapid in vivo killing by memory CD8T cells. J Immunol 2003, 171(1):27-31.
14. Pope C., Kim S.K., Marzo A., Masopust D., Williams K., Jiang J., et al. Organ-specific regulation of the CD8T cellresponse to Listeria monocytogenes infection. J. Immunol 2001, 166:3402-3409.
15. Jegerlehner A., Maurer P., Bessa J., Hinton H.J., Kopf M., Bachmann M.F. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007, 178:2415-2420.
16. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
17. Hoft D.F., Eickhoff C.S., Giddings O.K., Vasconcelos J.C., Rodrigues M.M. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 2007, 179:6889-6890.
18. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 10(6):403-414.
19. Jiang W., Lederman M.M., Harding C.V., Sieg S.F. Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naïve B cells. J Immunol 2011, 186:2080-2086.
20. Heit A., Huster K.M., Schmitz F., Schiemann M., Busch D.H., Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 2004, 172:1501-1507.
21. Bon A.L., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
22. Bon A.L., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., et al. Enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006, 176:2074-2078.
23. Van Uden J.H., Tran C.H., Carson D.A., Raz E. Type I interferon is required to mount an adaptive response to immunostimulatory DNA. Eur J Immunol 2001, 31:3281-3290.
24. Rosa D.S., Bastos K.R., Bargieri D.Y., Tzelepis F., Nomizo A., Russo M., et al. Role of interferon-γ during CpG oligodeoxynucleotide-adjuvanted immunization with recombinant proteins. Vaccine 2007, 25:6007-6017.
25. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202(1):135-143.
26. Xu H.L., Wang S.Q., Wang S.F., Guo F., Lu R.J., Ruan L. Delineation of CpG motifs for activating human immune cells. Chin J Microbiol Immunol 2001, 21(5):471-475.
27. Halperin S.A., Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen coadministered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.
28. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000, 164:944-953.